Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure (LENVAGIST)

A Multicentre, Comparative, Placebo-controlled, Double-blinded, Phase II Study of the Efficacy of Lenvatinib in Patients With Locally Advanced or Metastatic GIST After Failure of Imatinib and Sunitinib

The primary objective is to compare the efficacy of lenvatinib plus Best Supportive Care versus Placebo plus Best Supportive Care in the treatment of patients with advanced GIST, after failure of imatinib and sunitinib.

Study Overview

• Status: Recruiting
• Conditions: Gastro Intestinal Stromal Tumour
• Intervention / Treatment: Drug: Lenvatinib; Other: Best supportive care; Drug: Placebo

Detailed Description

Even though the prognosis of advanced GIST has been tremendously improved by the introduction of tyrosine kinase inhibitors, the vast majority of patients will develop secondary resistance to these agents.

The therapeutic options of patients with advanced GIST with resistance (or intolerance) to imatinib and sunitinib remain then very limited and prognosis of patients are very poor.

Nilotinib has an inferior activity in first line setting as compared to imatinib. Sorafenib has been evaluated in off-label and compassionate use studies with a median PFS close to 3 to 4 months, and a median overall survival close to 9 months with few prolonged tumor control and limited availability.

Regorafenib was tested in a phase II and a randomized phase III trial (GRID) in this setting , and provided a significant PFS advantage with no significant improvement in OS.

There are no recognized standard options in patients whose tumors progress after 3 or more TKIs. The recently updated guidelines from ESMO in 2014, included the reintroduction of imatinib in an attempt to control the progression of the sensitive cell clones, and on the basis of the results of the RIGHT study.

This is therefore a situation with a clear unmet medical need.

Lenvatinib is a broad spectrum TKI targeting oncogenes KIT and RET and receptor tyrosine kinases, PDGFRA, VEGFR 1-3 and FGFR 1-4. It has demonstrated activity in iodine resistant metastatic thyroid cancers. Whether lenvatinib would be a useful agent in patients with GIST is not known but there is a rationale to investigate its activity in patients with advanced GIST.

In the present study, we propose to analyze the antitumor activity of lenvatinib in patients with GIST failing to at least imatinib and sunitinib in a randomized setting, vs placebo.

• Study Type: Interventional
• Enrollment (Anticipated): 74
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Julien GAUTIER; Phone Number: +33 4.26.55.68.29; Email: julien.gautier@lyon.unicancer.fr

Study Locations

• France
  • Alpes-Maritimes
    • Nice, Alpes-Maritimes, France, 06189
      • Recruiting
      • Centre Antoine Lacassagne
      • Contact: Agnès DUCOULOMBIER; Email: agnes.ducoulombier@nice.unicancer.fr
      • Principal Investigator: Agnès DUCOULOMBIER, Dr
      • Sub-Investigator: Esma SAADA-BOUZID, Dr
      • Sub-Investigator: Ludovic EVESQUE, Dr
  • Bouches Du Rhône
    • Marseille, Bouches Du Rhône, France, 13385
      • Recruiting
      • Hopital de la Timone
      • Principal Investigator: Florence DUFFAUD, Pr
      • Sub-Investigator: Sébastien SALAS, Dr
      • Contact: Florence DUFFAUD, Pr; Email: florence.duffaud@ap-hm.fr
      • Sub-Investigator: Marie MEURER, Dr
  • Bouches-du-Rhône
    • Marseille, Bouches-du-Rhône, France, 13273
      • Recruiting
      • Institut Paoli Calmette
      • Principal Investigator: François BERTUCCI, Pr
      • Contact: François BERTUCCI, Pr; Email: bertuccif@ipc.unicancer.fr
      • Sub-Investigator: Simon LAUNAY, Dr
      • Sub-Investigator: Delphine LOUVEL-PERROT, Dr
      • Sub-Investigator: Elika LOIR, Dr
  • Bourgogne-Franche-Comté
    • Dijon, Bourgogne-Franche-Comté, France, 21079
      • Recruiting
      • Centre Georges-François Leclerc
      • Principal Investigator: Alice HERVIEU, Dr
      • Contact: Alice HERVIEU; Email: ahervieu@cgfl.fr
      • Sub-Investigator: Isabelle DESMOULINS, Dr
  • Gironde
    • Bordeaux, Gironde, France, 33076
      • Recruiting
      • Institut Bergonié
      • Sub-Investigator: Sophie COUSIN, Dr
      • Sub-Investigator: Maud TOULMONDE, Dr
      • Contact: Antoine ITALIANO, Pr; Email: a.italiano@bordeaux.unicancer.fr
      • Principal Investigator: Antoine ITALIANO, Pr
      • Sub-Investigator: Kévin BOURCIER, Dr
  • Haute-Garonne
    • Toulouse, Haute-Garonne, France, 31059
      • Recruiting
      • Institut Universitaire du Cancer de Toulouse Oncopole
      • Contact: Thibaud VALENTIN; Email: valentin.thibaud@iuct-oncopole.fr
      • Principal Investigator: Thibaud VALENTIN, Dr
      • Sub-Investigator: Christine CHEVREAU, Dr
      • Sub-Investigator: Iphigenie KORAKIS, Dr
      • Sub-Investigator: Ilfad BLAZEVIC, Dr
      • Sub-Investigator: Nadim FARES, Dr
      • Sub-Investigator: Carlos GOMEZ ROCA, Dr
  • Hauts-de-France
    • Lille, Hauts-de-France, France, 59020
      • Recruiting
      • Centre Oscar Lambret
      • Sub-Investigator: Diane PANNIER, Dr
      • Contact: Loïc LEBELLEC; Email: l-lebellec@o-lambret.fr
      • Principal Investigator: Loïc LEBELLEC, Dr
      • Sub-Investigator: Nicolas PENEL, Dr
      • Sub-Investigator: Thomas RYCKEWAERT, Dr
  • Ille-et-Vilaine
    • Rennes, Ille-et-Vilaine, France, 44229
      • Recruiting
      • Centre Eugene Marquis
      • Sub-Investigator: Christophe PERRIN, Dr
      • Contact: Marc PRATCH; Email: m.pracht@rennes.unicancer.fr
      • Principal Investigator: Marc PRATCH, Dr
      • Sub-Investigator: Héloïse BOURIEN, Dr
      • Sub-Investigator: Angélique BRUNOT, Dr
  • Loire-Atlantique
    • Saint-Herblain, Loire-Atlantique, France, 44805
      • Recruiting
      • ICO Centre Rene Gauducheau
      • Sub-Investigator: Frédéric ROLLAND, Dr
      • Sub-Investigator: Damien VANSTEENE, Dr
      • Sub-Investigator: Marie ROBERT, Dr
      • Sub-Investigator: Audrey ROLLOT, Dr
      • Contact: Emmanuelle BOMPAS, Dr; Email: emmanuelle.bompas@ico.unicancer.fr
      • Principal Investigator: Emmanuelle BOMPAS, Dr
      • Sub-Investigator: Cyriac BLONZ, Dr
      • Sub-Investigator: Judith RAIMBOURD, Dr
      • Sub-Investigator: Sandrine HIRET, Dr
      • Sub-Investigator: Mélanie SAINT-JEAN, Dr
  • Marne
    • Reims, Marne, France, 51000
      • Recruiting
      • CHU de Reims
      • Contact: Olivier BOUCHE, Pr; Email: obouche@chu-reims.fr
      • Sub-Investigator: Damien BOTSEN, Dr
      • Sub-Investigator: Mathilde BRASSEUR, Dr
  • Meurthe-et-Moselle
    • Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France, 54511
      • Recruiting
      • Institut de Cancérologie de Lorraine Alexis Vautrin
      • Principal Investigator: Maria RIOS, Dr
      • Contact: Maria RIOS; Email: m.rios@nancy.unicancer.fr
      • Sub-Investigator: Anne KIEFFER, Dr
  • Rhône
    • Lyon, Rhône, France, 69373
      • Recruiting
      • Centre Leon Berard
      • Contact: Jean-Yves BLAY; Email: jean-yves.blay@lyon.unicancer.fr
      • Sub-Investigator: Armelle DUFRESNE, Dr
      • Sub-Investigator: Hélène VANACKER, Dr
      • Sub-Investigator: Mehdi BRAHMI, Dr
      • Principal Investigator: Jean-Yves BLAY, Ph
      • Sub-Investigator: Isabelle RAY-COQUARD, Pr
      • Sub-Investigator: Mélodie CARBONNAUX, Dr
      • Sub-Investigator: Benoite MERY, Dr
  • Val-de-Marne
    • Villejuif, Val-de-Marne, France, 94805
      • Recruiting
      • Institut Gustave Roussy
      • Sub-Investigator: Sarah DUMONT, Dr
      • Sub-Investigator: Olivier MIR, Dr
      • Contact: Axel LE CESNE; Email: axel.lecesne@gustaveroussy.fr
      • Principal Investigator: Axel LE CESNE, Ph
      • Sub-Investigator: Rastislav BAHLEDA, Dr
      • Sub-Investigator: Benjamin VERRET, Dr
  • Vienne
    • Poitiers, Vienne, France, 86021
      • Recruiting
      • CHU Poitiers
      • Contact: Nicolas Isambert; Email: nicolas.isambert@chu-poitiers.fr
      • Principal Investigator: Nicolas ISAMBERT, Dr
      • Sub-Investigator: Aurélie FERRU, Dr
      • Sub-Investigator: Marjorie HIRSH, Dr
      • Sub-Investigator: David TOUGERON, Dr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

I1. Male or female ≥ 18 years at the day of consenting to the study.

I2. Patient must have histologically confirmed diagnosis of GIST.

I3. Disease must be locally advanced or metastatic.

I4. Patient who failed (disease progression and/or intolerance) previously at least to imatinib and sunitinib.

Nota Bene: patients with more than 2 previous anticancer treatments are eligible.

I5. Patient must have evidence of measurable disease as per the RECIST version 1.1 (Appendix 2).

I6. Patient must have documented disease progression. I7. ECOG performance status 0, 1 or 2 (Appendix 3).

I8. Patient must have normal organ and bone marrow function as defined below:

• Hematologic

  • Absolute neutrophil count (ANC) ≥ 1.5 Gi/L
  • Haemoglobin ≥ 9 g/dl (5.6 mmol/l) (subjects may not have had a transfusion within 7 days of screening assessment)
  • Platelets ≥ 100 Gi/l

• Coagulation panel

  • Prothrombin time (PT) or international normalized ratio (INR) ≤ 1.2 X upper limit of normal (ULN)
  • Partial thromboplastin time (PTT) ≤ 1.2 X ULN Subjects receiving anticoagulant therapy are eligible if their INR is stable and within the recommended range for the desired level of anticoagulation.

• Hepatic

  • Total bilirubin ≤ 1.5 X ULN
  • AST and ALT ≤ 2.5 X ULN

• Renal

  • Serum creatinine ≤ 1.5 mg/dl (133 µmol/l) Or, if greater than 1.5 mg/dl: calculated creatinine clearance ≥ 50 ml/min
  • Urine Protein to Creatinine ratio (UPC) < 1; If UPC > 1, then a 24-hour urine protein must be assessed. Subjects must have a 24-hour urine protein value <1g.

I9. Patient and his/her partner using an effective contraception as defined in Appendix 1.

I10. Patient able to understand and willingness for follow-up visits. I11. Patient covered by a medical insurance. I12. Signed and dated informed consent document indicating that the patient has been informed of all the pertinent aspects of the trial prior to any study-specific procedure.

Exclusion Criteria:

E1. Patient with a documented mutation in PDGFRA exon 18 (D842V substitution).

E2. Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to:

• Active peptic ulcer disease
• Known intraluminal metastatic lesions with risk of bleeding
• Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or other gastrointestinal conditions with increased risk of perforation
• History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days prior to beginning study treatment
• Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:
• Malabsorption syndrome
• Major resection of the stomach or small bowel.

E3. Any active/uncontrolled infection, including known infection with HIV, Hepatitis B or Hepatitis C.

E4. Corrected QT interval (QTc) > 480 msecs using Bazett's formula

E5. History of any one or more of the following cardiovascular conditions within the past 6 months prior to the first dose of study drug:

• Cardiac angioplasty or stenting
• Myocardial infarction
• Unstable angina
• Coronary artery bypass graft surgery
• Symptomatic peripheral vascular disease
• Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA) classification.

E6. Poorly controlled arterial hypertension (Systolic blood pressure: 150mmHg / Diastolic blood pressure: 90mmHg).

Note: Patients with high blood pressure can be enrolled provided that the hypertension is well controlled at a stable dose of antihypertensive therapy for at least 1 week prior to lenvatinib start).

E7. Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major).

E8. Evidence of active bleeding or bleeding diathesis. E9. Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels.

E10. Clinically significant haemoptysis within 8 weeks of first dose of study drug.

E11. Any serious and/or unstable pre-existing medical, psychiatric, or other condition (geographic, social…) that could interfere with subject's safety, provision of informed consent, or compliance to study procedures.

E12. Unable or unwilling to discontinue use of prohibited medications list in Section 6.3 for at least 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the study.

E13. Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or that is progressing in severity, except alopecia.

E14. Inability to swallow E15. Any contraindication to Lenvima®, according to its Summary of Product Characteristics E16. History of hypersensitivity or allergic reactions attributed to compounds of similar chemical or biologic composition of lenvatinib E17. Clinically significant unrelated systemic illness (e.g., serious infection or significant cardiac, pulmonary, hepatic, or other organ dysfunction) that would compromise the patient's ability to tolerate study treatment or would likely interfere with study procedures or results.

E18. Pregnant or breastfeeding women. Women of childbearing potential (Appendix 1) are required to have a negative serum pregnancy test within 72 hours prior to study treatment start. A positive urine test must be confirmed by a serum pregnancy test Note: Female if applicable, subjects should discontinue breast-feeding prior to the first dose of study drug and should refrain from breastfeeding throughout the treatment period and for 14 days following the last dose of study drug.

E19. Patient under tutorship or curatorship.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Lenvatinib + Best Supportive Care	Drug: Lenvatinib; Lenvatinib will be administered continuously but patient's follow-up visits will be scheduled monthly. The starting dose of study treatment is 24mg, once daily, at the same time. Recommendations for dose reductions will be respected according to BI Lenvatinib. If a patient misses a dose, and it cannot be taken within 12 hours, then that dose should be skipped and the next dose should be taken at the usual time of administration. Study treatments will be continued until a treatment discontinuation criteria is met.; Other: Best supportive care; At any time during the study, patients should receive best supportive care. Best Supportive care as medically indicated for the patient's well-being may be prescribed at the investigator's discretion. Based on the patient's condition, it may consist (but not limited) of analgesics, antibiotics, steroids, blood transfusion, antiemetics, antidepressants/anxiolytics, nutritional counselling, psychological support, palliative radiotherapy…
Placebo Comparator: Placebo + Best Supportive Care	Other: Best supportive care; At any time during the study, patients should receive best supportive care. Best Supportive care as medically indicated for the patient's well-being may be prescribed at the investigator's discretion. Based on the patient's condition, it may consist (but not limited) of analgesics, antibiotics, steroids, blood transfusion, antiemetics, antidepressants/anxiolytics, nutritional counselling, psychological support, palliative radiotherapy…; Drug: Placebo; Placebo will be administered continuously but patient's follow-up visits will be scheduled monthly. The starting dose of study treatment is 24mg, once daily, at the same time. Recommendations for placebo dose reductions are the same as for Lenvatinib. If a patient misses a dose, and it cannot be taken within 12 hours, then that dose should be skipped and the next dose should be taken at the usual time of administration. Study treatments will be continued until a treatment discontinuation criteria is met. In case disease progression, patients in control arm could switch in the Lenvatinib + BSC arm.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-Free Survival (PFS)	PFS, defined as the time from the date of randomisation to the date of the first documented radiological progression (RECIST 1.1) or death due to any cause. PFS will be estimated using the Kaplan-Meier method and will be described in terms of median PFS per arm, and hazard ratio for progression between the 2 arms. Associated 2-sided 95% CI for the estimates will be provided.	Up to 30 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival (OS)	OS, is defined as the time from the date of randomisation until the date of death due to any cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive.	Up to 30 months
Objective Response Rate (ORR) for patient in the blinded part of the study	ORR, is the proportion of patients with a Complete Response or Partial Response as Best Overall Response.	Up to 30 months
Best Overall Response (BOR) for patient in the blinded part of the study	BOR, is described as the proportion of patients with a best overall response of Complete Response, Partial Response, Stable Disease or Progressive Disease.	Up to 30 months
Quality of Life (QoL) for patient in the blinded part of the study	QoL, will be assessed using the EORTC QLQ-C30. Scores will be calculated at each time point according to the scoring manuals. Descriptive statistics will be used to evaluate baseline scores and evolution of scores from baseline to each time point. Data will be compared between arms using the Student's t-test.	Up to 30 months
Patient's tolerance to treatment	The safety will be described mainly on the frequency of adverse events coded using the common toxicity criteria (NCI-CTCAE v5.0) grade. Descriptive statistics will be provided for characterizing and assessing patient tolerance to treatment. Adverse events will be coded according to the MedDRA®.	Up to 30 months
Progression-Free Survival (PFS) In patients from the placebo arm who switched into the active treatment group	OS, is defined as the time from the date of randomisation until the date of death due to any cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive.	Up to 30 months

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mutation profile : KIT	Determined by immunohistochemistry (archival formalin fixed paraffin embedded tumor sample)	Inclusion
Mutation profile: PDGFR	Determined by immunohistochemistry (archival formalin fixed paraffin embedded tumor sample)	Inclusion
Pharmacokinetic properties of lenvatinib for patient in the blinded part of the study	Trough levels of lenvatinib	Inclusion, Day 1 of cycles 2, 3, 4, 5, up to 12 months (28 days cycle)

Collaborators and Investigators

• Sponsor: Centre Leon Berard
• Investigators: Principal Investigator: Axel LE CESNE, Ph, Gustave Roussy, Cancer Campus, Grand Paris

Study record dates

Study Major Dates

• Study Start (Actual): January 17, 2020
• Primary Completion (Anticipated): September 1, 2023
• Study Completion (Anticipated): September 1, 2024

Study Registration Dates

• First Submitted: December 5, 2019
• First Submitted That Met QC Criteria: December 9, 2019
• First Posted (Actual): December 10, 2019

Study Record Updates

• Last Update Posted (Actual): March 29, 2023
• Last Update Submitted That Met QC Criteria: March 28, 2023
• Last Verified: March 1, 2023

More Information

Terms related to this study

• Keywords: Tyrosine kinase inhibitors; Locally advanced or metastatic; Gastro Intestinal Stromal Tumour
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Neoplasms, Connective Tissue; Gastrointestinal Stromal Tumors; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Protein Kinase Inhibitors; Lenvatinib
• Other Study ID Numbers: ET18-291 - LENVAGIST

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No